MIER2

MIER2 is a predominantly nuclear ELM2-SANT domain transcriptional corepressor that assembles catalytically active histone deacetylase complexes (PMID:28046085). It recruits HDAC1, and in a cell-line-dependent manner HDAC2, through its ELM2 domain, with tryptophan 228 (W228) serving as a critical residue for this interaction (PMID:28046085); the resulting complexes possess intrinsic deacetylase activity that, unlike some other ELM2-SANT-associated HDACs, is unresponsive to IP4 (PMID:28046085). Functionally, MIER2-bound HDAC1 deacetylates P53, reducing its DNA-binding stability and transcriptional activity, thereby suppressing PGC1A transcription and driving intracellular lipid accumulation in renal cell carcinoma (PMID:38702028). The ELM2 domain additionally functions as a degron: conserved N-terminal residues within it are recognized by the Cul3-KBTBD4 E3 ubiquitin ligase to mediate UM171-induced proteasomal degradation of MIER2 (PMID:36997086). MIER2 does not heterodimerize with its paralogs MIER1 or MIER3 (PMID:28046085).

1. 2017 High

   Established that MIER2 is a nuclear corepressor that nucleates an enzymatically active HDAC complex and mapped the structural determinant of recruitment, defining its core molecular function.

   Evidence Confocal microscopy, reciprocal co-immunoprecipitation across HEK293/MCF7/HeLa, in vitro HDAC activity assay, and deletion plus site-directed mutagenesis of the ELM2 domain

   PMID:28046085

   Open questions at the time

   • Genomic loci and target genes bound by the MIER2-HDAC complex were not identified
   • Cell-line dependence of HDAC1 vs HDAC2 recruitment was not mechanistically explained
   • Structural basis for W228-mediated HDAC contact not resolved
2. 2023 Medium

   Answered how MIER2 protein levels are controlled, showing the ELM2 domain doubles as a degron for a specific E3 ligase under small-molecule induction.

   Evidence Global quantitative proteomics and mutational analysis of ELM2 N-terminal residues identifying Cul3-KBTBD4-mediated, UM171-induced degradation

   PMID:36997086

   Open questions at the time

   • Endogenous (UM171-independent) regulation of MIER2 stability not addressed
   • Direct ubiquitination sites on MIER2 not mapped
   • Functional consequence of MIER2 degradation on its HDAC complexes not tested
3. 2024 Medium

   Connected the MIER2-HDAC1 module to a defined downstream pathway, showing it deacetylates P53 to repress PGC1A and reprogram lipid metabolism in cancer.

   Evidence ChIP, western blot, co-immunoprecipitation, and cell-line plus animal models in renal cell carcinoma

   PMID:38702028

   Open questions at the time

   • Whether MIER2 directly binds chromatin at PGC1A or acts solely through P53 not fully resolved
   • Generality of the P53/PGC1A axis beyond renal cell carcinoma unknown
   • Single-lab functional model awaiting independent confirmation
4. 2026 Low

   Began resolving the architecture of the MIER2 corepressor complex, identifying an additional subunit and IDR-driven assembly.

   Evidence Crosslinking mass spectrometry with integrative structural modeling (I-TASSER, HADDOCK, AlphaFold) defining an HDAC1:MIER2:MHAP1 (C16orf87) complex (preprint)

   PMID:41928988

   Open questions at the time

   • Preprint with limited direct biochemical validation of the modeled complex
   • Functional role of MHAP1/C16orf87 within the complex not established
   • Stoichiometry and physiological relevance of the IDR-driven assembly untested

• The genome-wide target landscape and the physiological contexts that regulate endogenous MIER2 corepressor activity remain undefined.
• No genome-wide chromatin occupancy map for MIER2
• No structure of the W228-HDAC interface
• Roles outside renal cell carcinoma and beyond the P53/PGC1A axis uncharacterized